Ezetimibe and Simvastatin

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.

12.1 Mechanism of Action Ezetimibe and Simvastatin Tablets Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. Ezetimibe and simvastatin tablets contain ezetimibe and simvastatin, two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe and simvastatin tablets reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and increases HDL-C through dual inhibition of cholesterol absorption and synthesis. Ezetimibe Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine.

Systemic exposure to Ezetimibe and Simvastatin reflects Approximately 59% to 71% enteral uptake across labeled Ezetimibe and Simvastatin strengths absorption kinetics and phase i cyp3a4 hepatic clearance and subsequent renal metabolite filtration, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 6–16 hour t½ intervals for Ezetimibe and Simvastatin half-life window (maximum serum exposure occurs 2–4 hours after ezetimibe and simvastatin dosing response profile).

Dosing protocols (10 mg/1 / 80 mg/1 Tablet or 10 mg/1 / 20 mg/1 Tablet or 10 mg/1 / 40 mg/1 Tablet or 10 mg/1 / 10 mg/1 Tablet) balance efficacy (74.00% patient satisfaction across 13 logs) against headache (9.7% of reports), diarrhea (8.4% of reports), nasopharyngitis (7.8% of reports), with strict avoidance in contraindicated in patients with prior serious allergic response to ezetimibe and simvastatin (ndc 51407-190); severe baseline organ impairment where ezetimibe and simvastatin accumulation exceeds safe therapeutic margins.